

CASE 4-33243P1

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

LARRAINE M. GRAF
Type or print name

Lorraine M. Graf
Signature

9/10/2003
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

BAIR ET AL.

APPLICATION NO: 10/603,409

FILED: JUNE 25, 2003

FOR: INHIBITORS OF THE E2F-1/CYCLIN INTERACTION FOR CANCER
THERAPY

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Hesna J. Pfeiffer', is written over a horizontal line.

Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7903

Date: 9/10/03

ATTY. DOCKET NO.
4-33243P1
APPLICATION NO.
10/603,409
APPLICANT
BAIR ET AL.
FILING DATE
JUNE 25, 2003

Group

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,719,296	2/17/98	Acton, III et al.	548	550	10/28/96
	AB	5,720,720	2/24/98	Laske et al.	604	49	3/15/96
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 01/40142	6/7/01	PCT			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AN	EP 0666270	8/9/95	EPO			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Chen et al., "Selective Killing of Transformed Cells by Cyclin/Cyclin-Dependent Kinase 2 Antagonists", Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 4325-4329 (1999).
	AS	Sharma et al., "Identification of E2F-1/Cyclin A Antagonists", Bioorg. Med. Chem. Lett., Vol. 11, pp. 2449-2452 (2001).
	AT	Laske et al., "Tumor Regression with Regional Distribution of the Targeted Toxin TF-CRM107 in Patients with Malignant Brain Tumors", Nature Medicine, Vol. 3, No. 12, pp. 1362-1368 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.



FORM PTO 1449

(REV. 7-85)

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Sheet 2 of 2

ATTY. DOCKET NO.
4-33243P1
APPLICATION NO.
10/603,409
APPLICANT
BAIR ET AL.
FILING DATE
JUNE 25, 2003

Group

AA	Fueyo et al., "Overexpression of E2F-1 in Glioma Triggers Apoptosis and Suppresses Tumor Growth <i>In Vitro</i> and <i>In Vivo</i> ", <i>Nature Medicine</i> , Vol. 4, No. 6, pp. 685-690 (1998).
AB	Vivès et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus", <i>J. Biol. Chem.</i> , Vol. 272, No. 25, pp. 16010-16017 (1997).
AC	Bonfanti et al., "p21 ^{WAF1} -derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth", <i>Cancer Res.</i> , Vol. 57, pp. 1442-1446 (1997).
AD	Ball et al., "Cell-Cycle Arrest and Inhibition of Cdk4 Activity by Small Peptides Based on the Carboxy-Terminal Domain of p21 ^{WAF1} ", <i>Current Biology</i> , Vol. 7, No. 1, pp. 71-79 (1996).
AE	Adams et al., "Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors", <i>Mol. Cell. Biol.</i> , Vol. 16, No. 12, pp. 6623-6633 (1996).
AF	Chen et al., "Cyclin-Binding Motifs Are Essential for the Function of p21 ^{CIP1} ", <i>Mol. Cell. Biol.</i> , Vol. 16, No. 9, pp. 4673-4682 (1996).
AG	Krek et al., "Cyclin A-Kinase Regulation of E2F-1 DNA Binding Function Underlies Suppression of an S Phase Checkpoint", <i>Cell</i> , Vol. 83, pp. 1149-1158 (1995).
AH	Kowalik et al., "E2F1 Overexpression in Quiescent Fibroblasts Leads to Induction of Cellular DNA Synthesis and Apoptosis", <i>J. Virol.</i> , Vol. 69, No. 4, pp. 2491-2500 (1995).
AI	Wu et al., "p53 and E2F-1 Cooperate to Mediate Apoptosis", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 3602-3606 (1994).
AJ	A. Brinker, <i>Eur. Biochem.</i> <u>267</u> , 5085-5092 (2000) XP-002212270
AK	M.-A. Ikeda et al., <i>Molecular and Cellular Biology</i> , <u>13</u> , 11, 7029-7035 (Nov. 1993)
AL	PCT Search report, appln PCT/EP 01/15006, dates 18/09/2002
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.